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Abstract Biological aging is the gradual, progressive decline in system integrity that occurs with
advancing chronological age, causing morbidity and disability. Measurements of the pace of aging
are needed as surrogate endpoints in trials of therapies designed to prevent disease by slowing
biological aging. We report a blood-DNA-methylation measure that is sensitive to variation in pace
of biological aging among individuals born the same year. We first modeled change-over-time in 18
biomarkers tracking organ-system integrity across 12 years of follow-up in n = 954 members of the
Dunedin Study born in 1972–1973. Rates of change in each biomarker over ages 26–38 years were
composited to form a measure of aging-related decline, termed Pace-of-Aging. Elastic-net
regression was used to develop a DNA-methylation predictor of Pace-of-Aging, called
DunedinPoAm for Dunedin(P)ace(o)f(A)ging(m)ethylation. Validation analysis in cohort studies and
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the CALERIE trial provide proof-of-principle for DunedinPoAm as a single-time-point measure of a
person’s pace of biological aging.
Introduction
Aging of the global population is producing forecasts of rising burden of disease and disability
(Harper, 2014). Because this burden arises from multiple age-related diseases, treatments for single
diseases will not address the burden challenge (Goldman et al., 2013). Geroscience research sug-
gests an appealing alternative: treatments to slow aging itself could prevent or delay the multiple
diseases that increase with advancing age, perhaps with a single therapeutic approach (Glady-
shev, 2016; Kaeberlein, 2013). Aging can be understood as a gradual and progressive deteriora-
tion in biological system integrity (Kirkwood, 2005). This deterioration is thought to arise from an
accumulation of cellular-level changes. These changes, in turn, increase vulnerability to diseases
affecting many different organ systems (Kennedy et al., 2014; López-Otı́n et al., 2013). Animal
studies suggest treatments that slow the accumulation of cellular-level changes can extend healthy
lifespan (Campisi et al., 2019; Kaeberlein et al., 2015). However, human trials of these treatments
are challenging because humans live much longer than model animals, making it time-consuming
and costly to follow up human trial participants to test treatment effects on healthy lifespan. This
challenge will be exacerbated in trials that will give treatments to young or middle-aged adults, with
the aim to prevent the decline in system integrity that antedates disease onset by years. Involving
young and midlife adults in healthspan-extension trials has been approved for development by the
National Advisory Council on Aging (2019 CTAP report to NACA). In midlife trials of treatments to
slow aging, called geroprotectors (Moskalev et al., 2016), traditional endpoints such as disease
diagnosis or death are too far in the future to serve as outcomes. Translation of geroprotector treat-
ments to humans could be aided by measures that quantify the pace of deterioration in biological
system integrity in human aging. Such measures could be used as surrogate endpoints for healthy
lifespan extension (Justice et al., 2016; Justice et al., 2018; Moskalev et al., 2016), even with
young-to-midlife adult trial participants. A useful measure should be non-invasive, inexpensive, reli-
able, and highly sensitive to biological change.
Recent efforts to develop such measures have focused on blood DNA methylation as a biological
substrate highly sensitive to changes in chronological age (Fahy et al., 2019; Horvath and Raj,
2018). Methylation-clock algorithms have been developed to identify methylation patterns that char-
acterize individuals of different chronological ages. However, a limitation is that individuals born in
different years have grown up under different historical conditions (Schaie, 1967). For example, peo-
ple born 70 years ago experienced more exposure to childhood diseases, tobacco smoke, airborne
lead, and less exposure to antibiotics and other medications, and lower quality nutrition, all of which
leave signatures on DNA methylation (Bell et al., 2019). As a result, the clocks confound methylation
patterns arising from early-life exposures to methylation-altering factors with methylation patterns
related to biological aging during adulthood. An alternative approach is to study individuals who
were all born the same year, and find methylation patterns that differentiate those who have been
aging biologically faster or slower than their same-age peers. The current article reports four steps
in our work toward developing a blood DNA methylation measure to represent individual variation
in the pace of biological aging.
In Step 1, which we previously reported (Belsky et al., 2015), we collected a panel of 18 blood-
chemistry and organ-system-function biomarkers at three successive waves of the Dunedin
Study, which follows a 1972–73 population-representative one-year birth cohort (N = 1037). We
used repeated-measures data collected when Study members were aged 26, 32, and 38 years old to
quantify rates of biological change. We modelled the rate of change in each biomarker and calcu-
lated how each Study member’s personal rate-of-change on that biomarker differed from the cohort
norm. We then combined the 18 personal rates of change across the panel of biomarkers to com-
pute a composite for each Study member that we called the Pace of Aging. Pace of Aging repre-
sents a personal rate of multi-organ-system decline over a dozen years. Pace of Aging was normally
distributed, and showed marked variation among Study members who were all the same chronologi-
cal age, confirming that individual differences in biological aging do emerge already by age 38,
years before chronic disease onset.
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In Step 2, which we previously reported, we validated the Pace of Aging against known criteria.
As compared to other Study members who were the same chronological age but had slower Pace of
Aging, Study members with faster Pace of Aging performed more poorly on tests of physical func-
tion; showed signs of cognitive decline on a panel of dementia-relevant neuropsychological tests
from an early-life baseline; were rated as looking older based on facial photographs; and reported
themselves to be in worse health (Belsky et al., 2015). Subsequently, we reported that faster Pace
of Aging is associated with early-life factors important for aging: familial longevity, low childhood
social class, and adverse childhood experiences (Belsky et al., 2017), and that faster Pace of Aging
is associated with older scores on Brain Age, a machine-learning-derived measure of structural MRI
differences characteristic of different age groups (Elliott et al., 2019). Notably, Pace of Aging was
not well-correlated with published epigenetic age clocks, which were designed to measure how old
a person is rather than how fast they are aging biologically (Belsky et al., 2018b).
In Step 3, which we report here, we distill the Pace of Aging into a measurement that can be
obtained from a single blood sample. Here we focused on blood DNA methylation as an accessible
molecular measurement that is sensitive to changes in physiology occurring in multiple organ sys-
tems (Birney et al., 2016; Bolund et al., 2017; Chambers et al., 2015; Chu et al., 2017;
Hedman et al., 2017; Ma et al., 2019; Mill and Heijmans, 2013; Morris et al., 2017; Wahl et al.,
2017). We used data about the Pace of Aging from age 26 to 38 years in the Dunedin Study along
with whole-genome methylation data at age 38 years. Elastic-net regression was applied to derive
eLife digest People’s bodies age at different rates. Age-related biological changes that
increase the risk of disease and disability progress rapidly in some people. In others, these
processes occur at a slower pace, allowing those individuals to live longer, healthier lives. This
observation has led scientists to try to develop therapies that slow aging. The hope is that such
treatments could prevent or delay diseases like heart disease or dementia, for which older age is the
leading risk factor.
Studies in animals have identified treatments that extend the creatures’ lives and slow age-
related disease. But testing these treatments in humans is challenging. Our lives are much longer
than the worms, flies or mice used in the experiments. Scientists would have to follow human study
participants for decades to detect delays in disease onset or an extension of their lives. An
alternative approach is to try to develop a test that measures the pace of aging, or essentially “a
speedometer for aging”. This would allow scientists to more quickly determine if treatments slow
the aging process.
Now, Belsky et al. show a blood test designed to measure the pace of aging predicts which
people are at increased risk of poor health, chronic disease and an earlier death. First, data about
chemical changes to an individual’s DNA, called DNA methylation, were analyzed from white blood
cell samples collected from 954 people in a long-term health study known as “The Dunedin Study”.
Using the data, Belsky et al. then developed an algorithm – named “DunedinPoAm” – that
identified people with an accelerated or slowed pace of aging based on a single blood test. Next,
they used the algorithm on samples from participants in three other long-term studies. This verified
that those people the algorithm identified as aging faster had a greater risk of poor health,
developing chronic diseases or dying earlier. Similarly, those identified as aging more slowly
performed better on tests of balance, strength, walking speed and mental ability, and they also
looked younger to trained raters. Additionally, Belsky et al. used the test on participants in a
randomized trial testing whether restricting calories had potential to extend healthy lifespan. The
results suggested that the calorie restriction could counter the effects of an accelerated pace of
aging.
The test developed by Belsky et al. may provide an alternate way of measuring whether age-
slowing treatments work. This would allow faster testing of treatments that can extend the healthy
lifespan of humans. The test may also help identify individuals with accelerated aging. This might
help public health officials test whether policies or programs can help people lead longer, healthier
lives.
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an algorithm that captured DNA methylation patterns linked with variation among individuals in their
Pace of Aging. The algorithm is hereafter termed ‘DunedinPoAm’.
DunedinPoAm is qualitatively different from previously published DNA methylation measures of
aging that were developed by comparing older individuals to younger ones. Those measures, often
referred to as ‘clocks,’ are state measures. They estimate how much aging has occurred in an individ-
ual up to the point of measurement. DunedinPoAm is a rate measure. It is based on comparison of
longitudinal change over time in 18 biomarkers of organ-system integrity among individuals who are
all the same chronological age. DunedinPoAm estimates how fast aging is occurring during the years
leading up to the time of measurement. Rather than a clock that records how much time has passed,
DunedinPoAm is designed to function as a speedometer, recording how fast the subject is aging.
In Step 4, which we report here, we validated the DunedinPoAm in five ways. First, using the Dun-
edin Study, we tested if Study member’s DunedinPoAm measured when they were aged 38 years
could predict deficits in physical and cognitive functioning seven years later, when the cohort was
aged 45 years. Second, we applied the DunedinPoAm algorithm to DNA methylation data from a
second, cross-sectional, study of adults to evaluate patterning of DunedinPoAm by chronological
age and sex and to test correlations of DunedinPoAm with self-reported health and proposed meas-
ures of biological age, including three epigenetic clocks. Third, we applied the DunedinPoAm algo-
rithm to DNA methylation data from a third, longitudinal study of older men to test associations
with chronic-disease morbidity and mortality. Fourth, we applied the DunedinPoAm algorithm to
DNA methylation data from a fourth, longitudinal, study of young people to test if DunedinPoAm
was accelerated by exposure to poverty and victimization, factors which are known to shorten
healthy lifespan. Finally, to ascertain the potential usefulness of DunedinPoAm as a measure for trials
of geroprotector treatments, we applied the algorithm to DNA methylation data from a randomized
trial of caloric restriction, CALERIE (Ravussin et al., 2015). Earlier we reported from this trial that
the intervention (two years of prescribed 25% caloric restriction) slowed the rate of biological aging
as measured by a blood-chemistry biological-age composite measure (Belsky et al., 2018a). Here,
using newly generated methylation data from blood drawn at the CALERIE baseline assessment, we
tested if (a) DunedinPoAm from blood drawn before caloric restriction could predict the future rate
of biological aging of participants during the two-year trial, and (b) if this prediction was disrupted in
participants who underwent caloric restriction, but not among control participants.
We report promising results from this four-step research program, while appreciating that addi-
tional measurement development will be needed to support applied use of DunedinPoAm. A graph-
ical illustration of our study design is presented in Figure 1.
Results
Capturing Pace of Aging in a single blood test
We derived the DunedinPoAm algorithm using data from Dunedin Study members for whom age-38
DNA methylation data were available (N = 810). We applied elastic-net regression (Zou and Hastie,
2005) using Pace of Aging between ages 26 to 38 years as the criterion. We included all methylation
probes that appear on both the Illumina 450 k and EPIC arrays as potential predictor variables. We
selected this overlapping set of probes for our analysis to facilitate application of the derived algo-
rithm by other research teams using either array. We fixed the alpha parameter to 0.5, following the
approach reported by Horvath (2013). This analysis selected a set of 46 CpG sites
(Supplementary file 1A). The 46-CpG elastic-net-derived DunedinPoAm algorithm, applied in the
age-38 Dunedin DNA methylation data, was associated with the longitudinal 26–38 Pace of Aging
measure (Pearson r = 0.56, Figure 1—figure supplement 1). This is likely an overestimate of the
true out-of-sample correlation because the analysis is based on the same data used to develop the
DunedinPoAm algorithm; bootstrap-cross-validation analysis estimated the out-of-sample correlation
to be r = 0.33 (Figure 1—figure supplement 2).
DunedinPoAm in midlife predicted future functional limitations
Physical functioning
As a primary criterion validity analysis of DunedinPoAm, we tested prospective associations of Dune-
din Study members’ age-38 DunedinPoAm values with their performance seven years later, when
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Figure 1. Schematic of design and follow-up of DunedinPoAm. DunedinPoAm is designed to quantify the rate of decline in system integrity
experienced by an individual over the recent past; it functions like speedometer for the rate of aging. We developed DunedinPoAm from analysis of
longitudinal change in 18 biomarkers of organ system integrity in the Dunedin Longitudinal Study birth cohort. Biomarkers were measured in 1998,
2004, and 2010, when all cohort members were aged 26, 32, and 38 years. We composited rates of change across the 18 biomarkers to produce a
single measure of aging-related decline in system integrity, termed Pace of Aging. We then used elastic-net regression to develop a DNA-methylation
predictor of Pace of Aging, called DunedinPoAm for Dunedin (P)ace (o)f (A)ging (m)ethylation. DNA methylation data for this analysis came from the
age-38 assessment in 2010. We further evaluated the performance of DunedinPoAm using data from (a) the age-45 assessments of Dunedin Study
members in 2018, (b) the Understanding Society Study, (c) the Normative Aging Study, (d) the E-risk Study, and (e) the CALERIE trial.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Association of DunedinPoAm with 12 year longitudinal Pace of Aging in the Dunedin Study.
Figure supplement 2. Bootstrap repetition analysis to estimate out-of-sample correlation between methylation Pace of Aging (mPoA) measures and
longitudinal Pace of Aging in the Dunedin Study.
Figure supplement 3. Correlations of individual biomarker slopes with DunedinPoAm plotted against their correlations with 12 year longitudinal Pace
of Aging.
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they were aged 45 years, on tests of balance, walking speed, chair stands, grip strength, motor coor-
dination, and Study-member reports about physical limitations. Performance scores were reversed
so that positive correlations indicated an association between faster DunedinPoAm (i.e. higher val-
ues) and worse physical performance. Study members with faster DunedinPoAm at age 38 per-
formed more poorly at age 45 on all physical performance tests, with the exception of grip strength,
and reported more functional limitations (standardized effect-sizes for tests of balance, walking
speed, chair stands, and physical limitations r = 0.15–0.29, p<0.001 for all; grip strength r = 0.05,
95% CI [ 0.02–0.12], p=0.162). Effect-sizes are graphed in the dark blue bars in Figure 2, Panel A.
Physical decline
For balance, grip strength, motor coordination, and functional limitations, the Dunedin study admin-
istered the same assessments at the age-38 and age-45 assessments. We used these data to mea-
sure change in physical function across the 7 year interval. We computed change scores by
subtracting the age-45 score from the age-38 score. Change scores for balance and physical limita-
tions indicated worsening of physical functioning across the 7 year interval (in terms of age-38 stan-
dard-deviation units (SDs): balance declined by 0.26 SDs 95% CI [0.19–0.33], motor coordination
declined by 0.16 [0.10–0.22] SDs, and physical limitations increased by 0.26 [0.18–0.33] SDs). In con-
trast, grip strength increased slightly (0.05 [0.00–0.11] SDs). Study members with faster age-38 Dun-
edinPoAm experienced greater decline in balance at age 45 (r = 0.11 [0.04–0.19], p=0.008) and a
greater increase in physical limitations (r = 0.10 [0.02–0.18], p=0.012). The association with change in
motor coordination was consistent in direction, but was not statistically different from zero at the
alpha = 0.05 threshold (r = 0.06 [ 0.14–0.01], p=0.109). There was no association between Dunedin-
PoAm and change in grip strength (r = 0.00 [ 0.07–0.08], p=0.897). Effect-sizes are graphed in the
top two rows of Figure 2, Panel B.
Cognitive functioning
We evaluated cognitive functioning from tests of perceptual reasoning, working memory, and proc-
essing speed, which are known to show aging related declines already by the fifth decade of life
(Hartshorne and Germine, 2015; Park et al., 2002). Study members with faster age-38 Dunedin-
PoAm performed more poorly on all age-45 cognitive tests (r = 0.14–0.28, p<0.001 for all). Effect-
sizes are graphed in the light-blue bars of Figure 2, Panel A.
Cognitive decline
Cognitive functioning in early life is a potent risk factor for chronic disease and dementia in later life
and for accelerated aging in midlife (Belsky et al., 2017; Deary and Batty, 2006). Therefore, to
evaluate whether associations between DunedinPoAm and cognitive test performance at age 45
might reflect reverse causation instead of early cognitive decline, we next conducted analysis of cog-
nitive decline between adolescence and midlife. We evaluated cognitive decline by comparing
Study-members’ cognitive-test performance at age 45 to their cognitive-test performance three dec-
ades earlier when they were ages 7–13 years. Cognitive performance was measured from composite
scores on the Wechsler Intelligence Scales (the Wechsler Adult Intelligence Scales Version IV at the
age-45 assessment and the Wechsler Intelligence Scales for Children Version R at the earlier time-
points). On average, Study members showed a decline of 2.00 IQ points (95% CI [1.31–2.70]) across
the follow-up interval. We conducted two analyses to test if participants with faster DunedinPoAm
experienced more cognitive decline. First, we computed difference scores (age-45 IQ – childhood
baseline IQ) and regressed these difference scores on DunedinPoAm. Second, we conducted analy-
sis of residualized change by regressing age-45 IQ on DunedinPoAm and childhood IQ. Both analy-
ses found that Study members with faster DunedinPoAm experienced more decline (difference-
score r = 0.12, [0.05–0.19], p=0.001; residualized change r = 0.20 [0.13–0.27]). The DunedinPoAm
association with cognitive decline is graphed in the third row of Figure 2, Panel B.
Subjective signs of aging
We evaluated subjective signs of aging from Study members’ ratings of their current health status
(excellent, very-good, good, fair, poor) and from ratings of perceived age made by undergraduate
raters based on facial photographs. Study members with faster age-38 DunedinPoAm rated
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themselves to be in worse health at age 45 (r = 0.27, 95% CI [0.20–0.34]). These Study members
were also rated as looking older (r = 0.35 [0.28–0.43]). Effect-sizes are graphed in the orange bars in
Figure 2, Panel A.
Subjective signs of decline with aging
We next analyzed change in subjective signs of aging. Across the 7 year follow-up interval, an
increasing number of Study members rated themselves as being in fair or poor health (6% rated their
health as fair or poor at age 38, as compared to 8% 7 years later at age 45). Those with faster age-
38 DunedinPoAm were more likely to transition to the fair/poor categories (Incidence Rate Ratio
Figure 2. Faster age-38 DunedinPoAm is associated with poorer physical and cognitive functioning and subjective signs of aging at age 45 years, and
with physical, cognitive, and subjective decline in the Dunedin Study. Panel A graphs effect-sizes for age-38 DunedinPoAm associations with age-45
measures of physical and cognitive functioning and subjective signs of aging in the Dunedin Study. Effect-sizes are standardized regression coefficients
interpretable as Pearson r. Models included covariate adjustment for sex. Panel B graphs associations between DunedinPoAm and change in physical
functioning between age 38 and age 45 (top two rows), change in cognitive functioning between age 13 and age 45 (third row), and incident fair/poor
health and accelerated facial aging between ages 38 and 45 (bottom row). Graphs for changes in balance, grip-strength, physical limitations, cognition,
and facial aging are binned scatterplots. Plotted points reflect average x- and y-coordinates for ‘bins’ of approximately ten Study members. Fitted
slopes show the association estimated from the raw, un-binned data. The y-axis scale on graphs of balance, grip-strength, and physical limitations
shows change scores (age 45 – age 38) scaled in terms of age-38 standard deviation units. The y-axis scale on the graph of cognitive change shows the
difference in IQ score (age 45 – baseline). The graph of change in facial aging shows the change in z-score between measurement intervals (age 45 –
age 38). Models included covariate adjustment for sex. The graph for self-rated health plots the predicted probability (fitted slope) and 95% confidence
interval (shaded area) of incident fair/poor health at age 45. The effect-size reported on the graph is the incidence-rate ratio (IRR) associated with a 1-
SD increase in DunedinPoAm estimated from Poisson regression. The model included covariate adjustment for sex.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Association of DunedinPoAm and 12 year longitudinal Pace of Aging with age-45 healthspan characteristics in the Dunedin
Study.
Figure supplement 2. Effect-sizes for association of DunedinPoAm and epigenetic clocks with age-45 healthspan characteristics in the Dunedin Study.
Figure supplement 3. Effect-sizes for association of DunedinPoAm and epigenetic clocks with change over time in healthspan characteristics in the
Dunedin Study.
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(IRR) = 1.79 95% CI [1.48–2.18]). We tested if Study members with faster DunedinPoAm experienced
more rapid facial aging by subtracting the age-45 score from the age-38 score and regressing this
difference on DunedinPoAm. This analysis tested if Study members with faster DunedinPoAm experi-
enced upward rank mobility within the cohort in terms of how old they looked. Study members with
faster age-38 DunedinPoAm were rated as looking older relative to peers at age 45 than they had
been at age 38 (r = 0.10 [0.03–0.18]). Effect-sizes are graphed in the bottom row of Figure 2, Panel
B.
Comparing DunedinPoAm versus Pace of Aging
We compared DunedinPoAm effect-sizes to effect-sizes for the original, 18-biomarker 3-time-point
Pace of Aging. Across the domains of physical function, cognitive function, and subjective signs of
aging, DunedinPoAm effect-sizes were similar to and sometimes larger than effect-sizes for the origi-
nal Pace of Aging measure (Supplementary file 1B, Figure 2—figure supplement 1).
Covariate adjustment to models for estimated cell counts (Houseman et al., 2012) did not
change results. Covariate adjustment for smoking history at age 38 years modestly attenuated some
effect-sizes and attenuated DunedinPoAm associations with cognitive decline to near zero. Results
for all models are reported in Supplementary file 1C.
In comparison to DunedinPoAm, effect-sizes for associations with functional limitations were
smaller for the Horvath, Hannum, and Levine epigenetic clocks and, in the cases of the Horvath and
Hannum clocks, were not statistically different from zero at the alpha = 0.05 threshold for most out-
comes. Effect-sizes are reported in Supplementary file 1C and plotted in Figure 2—figure supple-
ments 2 and 3.
Evaluating DunedinPoAm and other methylation clocks in the
Understanding Society Study
To test variation in DunedinPoAm and to compare it with published methylation measures of biolog-
ical aging, we conducted analysis using data on N = 1175 participants aged 28–95 years (M = 58,
SD = 15; 42% male) in the UK Understanding Society Study. In this mixed-age sample, the mean
DunedinPoAm was 1.03 years of biological aging per each calendar year (SD = 0.07).
We first tested if higher DunedinPoAm levels, which indicate faster aging, were correlated with
older chronological age. Mortality rates increase with advancing chronological age, although there
may be some slowing at the oldest ages (Barbi et al., 2018). This suggests the hypothesis that the
rate of aging increases across much of the adult lifespan. Consistent with this hypothesis, Under-
standing Society participants who were of older chronological age tended to have faster Dunedin-
PoAm (r = 0.11, [0.06–0.17], p<0.001; Figure 3 Panel A). We also compared DunedinPoAm with
three methylation measures of biological age: the epigenetic clocks proposed by Horvath, Hannum,
and Levine (Hannum et al., 2013; Horvath, 2013; Levine et al., 2018). These epigenetic clocks
were highly correlated with chronological age in the Understanding Society sample (Horvath Clock
r = 0.91, Hannum Clock r = 0.92, Levine Clock r = 0.88).
Next, to test if DunedinPoAm captured similar information about aging to published epigenetic
clocks, we regressed each of the published clocks on chronological age and predicted residual val-
ues, following the procedure used by the developers of the clocks. These residuals are referred to in
the literature as measures of ‘epigenetic age acceleration.’ None of the 46 CpGs included in the
DunedinPoAm algorithm overlapped with CpGs in these epigenetic clocks. Nevertheless, Dunedin-
PoAm was moderately correlated with epigenetic age acceleration measured from the clocks pro-
posed by Hannum (r = 0.24) and Levine (r = 0.30). DunedinPoAm was less-well correlated with
acceleration measured from the Horvath clock (r = 0.06). Associations among DunedinPoAm and the
epigenetic clocks in the Understanding Society sample are shown in Figure 3 Panel B.
Finally, we tested correlations of DunedinPoAm with (a) a measure of biological age derived from
blood chemistry and blood pressure data, and (b) a measure of self-rated health. We computed bio-
logical age from Understanding Society blood chemistry and blood pressure data following the Kle-
mera and Doubal method (KDM) (Klemera and Doubal, 2006) and the procedure described by
Levine (2013). KDM Biological Age details are reported in the Materials and Methods. Participants
with faster DunedinPoAm had more advanced KDM Biological Age (r = 0.20 95% CI [0.15–0.26],
p<0.001;) and worse self-rated health (r =  0.22 [-0.28,–0.16], p<0.001;). Covariate adjustment to
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models for estimated cell counts (Houseman et al., 2012) and smoking status did not change
results. Results for all models are reported in Supplementary file 1D.
In comparison to DunedinPoAm, effect-sizes for associations with self-rated health and KDM Bio-
logical Age were smaller for the epigenetic clocks and, in the cases of the Horvath and Hannum
clocks, were not statistically different from zero at the alpha = 0.05 threshold (Figure 3 Panels C and
D). Effect-sizes are reported in Supplementary file 1D and plotted in Figure 3—figure supplement
1.
Figure 3. Associations of DunedinPoAm with chronological age, epigenetic clocks, KDM Biological Age, and self-rated health in Understanding
Society. Panel A shows a scatterplot and fitted slopes illustrating the association between chronological age (x-axis) and DunedinPoAm (y-axis) in
women and men in the Understanding Society sample. Data for women are plotted with yellow dots (orange slope) and for men with blue crosses (navy
slope). The figure illustrates a positive association between chronological age and DunedinPoAm (Pearson r = 0.11 95% CI [0.06–0.17]). Panel B shows a
matrix of correlations and association plots among DunedinPoAm and age-acceleration residuals of the Horvath, Hannum, and Levine epigenetic
clocks. The diagonal cells of the matrix list the DNA methylation measures. The half of the matrix below the diagonal shows scatter plots of
associations. For each scatter-plot cell, the y-axis corresponds to the variable named along the matrix diagonal to the right of the plot and the x-axis
corresponds to the variable named along the matrix diagonal above the plot. The half of the matrix above the diagonal lists Pearson correlations
between the DNA methylation measures. For each correlation cell, the value reflects the correlation of the variables named along the matrix diagonal
to the left of the cell and below the cell. Panel C graphs binned scatterplots of associations of DunedinPoAm and epigenetic clocks with KDM
Biological Age advancement (the difference between KDM Biological Age and chronological age). Each plotted point shows average x- and y-
coordinates for ‘bins’ of approximately 50 participants. Regression slopes are graphed from the raw, un-binned data. Panel D plots average values of
the DNA methylation variables by Understanding Society participants’ self-rated health status. Error bars show 95% confidence intervals.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Effect-sizes for associations of DunedinPoAm and epigenetic clocks with KDM Biological Age and self-rated health in
Understanding Society.
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DunedinPoAm was associated with chronic disease morbidity and
increased risk of mortality among older men in the Normative Aging
Study (NAS)
To test if faster DunedinPoAm was associated with morbidity and mortality, we analyzed data from
N = 771 older men in the Veterans Health Administration Normative Aging Study (NAS; at baseline,
mean chronological age = 77, SD = 7).
We first tested if higher DunedinPoAm levels, which indicate faster aging, were associated with
increased risk of mortality. During follow-up from 1999 to 2013, 46% of NAS participants died over a
mean follow-up of 7 years (SD = 7). Those with faster DunedinPoAm at baseline were at increased
risk of death (Hazard Ratio (HR) = 1.29 [1.16–1.45], p<0.001; Figure 4).
We next tested if NAS participants with faster DunedinPoAm experienced higher levels of chronic
disease morbidity, measured as the count of diagnosed diseases (hypertension, type-2 diabetes, car-
diovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, and cancer). Dur-
ing follow-up across 4 assessments during 1999–2013 (n = 1448 observations of the N = 771
participants), n = 175 NAS participants were diagnosed with a new chronic disease. Those with
faster baseline DunedinPoAm were at increased risk of new diagnosis (HR = 1.19 [1.03–1.38],
p<0.019). In repeated-measures analysis of prevalent chronic disease, faster DunedinPoAm was
associated with having a higher level of chronic disease morbidity (IRR = 1.15 [1.11–1.20], p<0.001).
Finally, we utilized the repeated-measures data to test if NAS participants’ DunedinPoAms
increased as they aged. We tested within-person change in DunedinPoAm over time (n = 1253
observations of N = 536 participants with 2–4 timepoints of DNA methylation data). Consistent with
Understanding Society analysis showing faster DunedinPoAm in older as compared to younger
adults, NAS participants’ DunedinPoAm values increased across repeated assessments. For every
five years of follow-up, participants’ DunedinPoAms increased by 0.012 (SE = 0.002, p<0.001) units,
or about 0.2 standard deviations.
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Figure 4. Association of DunedinPoAm with mortality in the Normative Aging Study (NAS). The figure plots Kaplan-Meier curves for three groups of
NAS participants: those with DunedinPoAm 1 SD or more below the mean (‘slow’ DunedinPoAm, blue line); those with DunedinPoAm within 1 SD of
the mean (‘average’ DunedinPoAm, gray line); and those with DunedinPoAm 1 SD or more above the mean (‘fast’ DunedinPoAm, red line). Censoring
of participants prior to death is indicated with a vertical gray hash mark. The table below the figure details the number of participants at risk per 3 year
interval and, in parentheses, the number who died during the interval. The number censored can be calculated by subtracting the number of deaths in
an interval from the difference between the number at risk in that interval and the number at risk in the following interval.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Effect-sizes for association of DunedinPoAm and epigenetic clocks with mortality and morbidity in the Normative Aging Study.
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Covariate adjustment to models for estimated cell counts (Houseman et al., 2012) and smoking
status did not change results, with the exception that the effect-size for DunedinPoAm was attenu-
ated below the alpha = 0.05 threshold of statistical significance in smoking-adjusted analysis of
chronic disease incidence. Results for all models are reported in Supplementary file 1E.
In comparison to DunedinPoAm, effect-sizes for associations with mortality and chronic disease
were smaller for the epigenetic clocks and were not statistically different from zero in many of the
models (Supplementary file 1E and Figure 4—figure supplement 1).
Childhood exposure to poverty and victimization were associated with
faster DunedinPoAm in young adults in the E-Risk Study
To test if DunedinPoAm indicated faster aging in young people with histories of exposure thought
to shorten healthy lifespan, we analyzed data from N = 1658 members of the E-Risk Longitudinal
Study. The E-Risk Study follows a 1994–95 birth cohort of same-sex twins. Blood DNA methylation
data were collected when participants were aged 18 years. We analyzed two exposures associated
with shorter healthy lifespan, childhood low socioeconomic status and childhood victimization.
Socioeconomic status was measured from data on parents’ education, occupation, and income
(Trzesniewski et al., 2006). Victimization was measured from exposure dossiers compiled from
interviews with the children’s mothers and home-visit assessments conducted when the children
were aged 5, 7, 10, and 12 (Fisher et al., 2015). The dossiers recorded children’s exposure to
domestic violence, peer bullying, physical and sexual harm by an adult, and neglect. 72% of the anal-
ysis sample had no victimization exposure, 21% had one type of victimization exposure, 4% had two
types of exposure, and 2% had three or more types of exposure.
E-Risk adolescents who grew up in lower socioeconomic-status families exhibited faster Dunedin-
PoAm (Cohen’s d for comparison of low to moderate SES = 0.21 [0.06–0.35]; Cohen’s d for compari-
son of low to high SES = 0.44 [0.31–0.56]; Pearson r = 0.19 [0.13–0.24]). In parallel, E-Risk
adolescents with exposure to more types of victimization exhibited faster DunedinPoAm (Cohen’s d
for comparison of never victimized to one type of victimization = 0.28 [0.15–0.41]; Cohen’s d for
comparison of never victimized to two types of victimization = 0.48 [0.23–0.72]; Cohen’s d for com-
parison of never victimized to three or more types of victimization = 0.53 [0.25–0.81]; Pearson
r = 0.15 [0.10–0.20]). Covariate adjustment to models for estimated cell counts (Houseman et al.,
2012) did not change results. Adjustment for smoking status attenuated effect-sizes by about half,
but most associations remained statistically different from zero at the alpha = 0.05 level. Results for
all models are reported in Supplementary file 1F. Differences in DunedinPoAm across strata of
childhood socioeconomic status and victimization are graphed in Figure 5.
In comparison to DunedinPoAm, effect-sizes for associations with childhood socioeconomic cir-
cumstances and victimization were smaller for the epigenetic clocks and, in the cases of the Horvath
and Hannum clocks, were not statistically different from zero at the alpha = 0.05 threshold. Effect-
sizes are reported in Supplementary file 1F and plotted in Figure 5—figure supplement 1.
DunedinPoAm measured at baseline in the CALERIE randomized trial
predicted future rate of aging measured from clinical-biomarker data
The CALERIE Trial is the first randomized trial of long-term caloric restriction in non-obese adult
humans. CALERIE randomized N = 220 adults on a 2:1 ratio to treatment of 25% caloric restriction
(CR-treatment) or control ad-libitum (AL-control, as usual) diet for two years (Ravussin et al., 2015).
We previously reported that CALERIE participants who were randomized to CR-treatment experi-
enced a slower rate of biological aging as compared to participants in the AL-control arm based on
longitudinal change analysis of clinical-biomarker data from the baseline, 12 month, and 24 month
follow-up assessments (Belsky et al., 2018a). Among control participants, the rate of increase in bio-
logical age measured using the Klemera-Doubal method (KDM) Biological Age algorithm was 0.71
years of biological age per 12 month follow-up interval. (This slower-than-expected rate of aging
could reflect differences between CALERIE Trial participants, who were selected for being in good
health, and the nationally representative NHANES sample in which the KDM algorithm was devel-
oped [Belsky et al., 2018a].) In contrast, among treatment participants, the rate of increase was
only 0.11 years of biological age per 12 month follow-up interval (difference b =  0.60 [-0.99,–
0.21]). We subsequently generated DNA methylation data from blood DNA that was collected at
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the baseline assessment of the CALERIE trial for a sub-sample (N = 68 AL-control participants and
118 CR-treatment participants). We used these methylation data to calculate participants’ Dunedin-
PoAm values at study baseline. We then tested if baseline DunedinPoAm could predict participants’
future rate of biological aging as they progressed through the trial.
We first replicated our original analysis within the methylation sub-sample. Results were the same
as in the full sample (Supplementary file 1G). Next, we compared DunedinPoAm between CR-treat-
ment and AL-control participants. As expected, there was no group difference at baseline (AL
M = 1.00, SD = 0.05; CR M = 1.01, SD = 0.06, p-value for difference = 0.440). Finally, we tested if
participants’ baseline DunedinPoAm was associated with their rate of biological aging over the 24
months of follow-up, and if this association was modified by randomization to caloric restriction as
compared to ad libitum diet. For AL-control participants, faster baseline DunedinPoAm predicted
faster biological aging over the 24 month follow-up, although in this small group this association was
not statistically significant at the alpha = 0.05 level (b = 0.22 [-0.05, 0.49], p=0.104). For CR-treat-
ment participants, the association of baseline DunedinPoAm with future rate of aging was sharply
reduced, (b =  0.08 [-0.24, 0.09], p=0.351), although the difference between the rate of aging in
the AL-control and CR-treatment groups did not reach the alpha = 0.05 threshold for statistical sig-
nificance (interaction-term testing difference in slopes b =  0.30 [-0.61, 0.01], p-value=0.060).
Slopes of change in KDM Biological Age for participants in the AL-control and CR-treatment groups
are plotted for fast baseline DunedinPoAm (1 SD above the mean) and slow baseline DunedinPoAm
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Figure 5. DunedinPoAm levels by strata of childhood socioeconomic status (SES) and victimization in the E-Risk
Study. Panel A (left side) plots means and 95% CIs for DunedinPoAm measured at age 18 among E-Risk
participants who grew up low, middle, and high socioeconomic status households. Panel B (right side) plots
means and 95% CIs for DunedinPoAm measured at age 18 among E-Risk participants who experienced 0, 1, 2, or
three or more types of victimization through age 12 years.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Effect-sizes for associations of childhood socioeconomic status and victimization exposure
with DunedinPoAm and epigenetic clocks.
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(1 SD below the mean) in Figure 6. CALERIE DNA methylation data are not yet available to test if
the intervention altered post-treatment DunedinPoAm.
Discussion
Breakthrough discoveries in the new field of geroscience suggest opportunities to extend healthy life-
span through interventions that slow biological processes of aging (Campisi et al., 2019). To advance
translation of these interventions, measures are needed that can detect changes in a person’s rate of
biological aging (Moffitt et al., 2017). We previously showed that the rate of biological aging can be
measured by tracking change over time in multiple indicators of organ-system integrity (Belsky et al.,
2015). Here, we report data illustrating the potential to streamline measurement of Pace of Aging to
an exportable, inexpensive and non-invasive blood test, and thereby ease implementation of Pace of
Aging measurement in studies of interventions to slow processes of biological aging.
We conducted machine-learning analysis of the original Pace of Aging measure using elastic-net
regression and whole-genome blood DNA methylation data. We trained the algorithm to predict
how fast a person was aging. We called the resulting algorithm ‘DunedinPoAm’ for ‘ (P)ace (o)f (A)
ging (m)ethylation’. There were four overall findings:
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Figure 6. Change in KDM Biological Age over 24 month follow-up by treatment condition and baseline
DunedinPoAm in the CALERIE Trial. Fast DunedinPoAm is defined as 1 SD above the sample mean. Slow
DunedinPoAm is defined as 1 SD below the sample mean. Slopes are predicted values from mixed effects
regression including a 3-way interaction between trial condition, time, and continuous DunedinPoAm at baseline.
The figure shows that in the Ad Libitum (AL) arm of the trial, participants with fast DunedinPoAm at baseline
experience substantially more change in KDM Biological Age from baseline to follow-up as compared to AL
participants with slow DunedinPoAm. In contrast, there was little difference between participants with fast as
compared to slow DunedinPoAm in the Caloric Restriction (CR) arm of the trial.
The online version of this article includes the following figure supplement(s) for figure 6:
Figure supplement 1. Effect-sizes for associations of DunedinPoAm and epigenetic clocks with future rate of
change in KDM Biological Age in Ad Libitum (AL) control group and Caloric Restriction (CR) intervention group
participants in the CALERIE Trial.
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First, while DunedinPoAm was not a perfect proxy of Pace of Aging, it nevertheless captured criti-
cal information about Dunedin Study members’ healthspan-related characteristics. Across the
domains of physical function, cognitive function, and subjective signs of aging, Study members with
faster DunedinPoAm at age 38 were worse off seven years later at age 45 and, in repeated-measures
analysis of change, they showed signs of more rapid decline. Effect-sizes were equal to or greater
than those for the 18-biomarker 3-time point measure of Pace of Aging. This result suggests that the
DNA-methylation elastic-net regression used to develop DunedinPoAm may have distilled the aging
signal from the original Pace of Aging measure and excluded some noise. In sum, DunedinPoAm
showed promise as an easy-to-implement alternative to Pace of Aging. Emerging technologies for
deep-learning analysis (Zhavoronkov et al., 2019) may improve methylation measurement of Pace
of Aging. Alternatively, integration of methylation data with additional molecular datasets
(Hasin et al., 2017; Zierer et al., 2015) may be needed to achieve precise measurement of Pace of
Aging from a single time-point blood sample.
Second, DunedinPoAm analysis of the Understanding Society and NAS samples provided proof-
of-concept for using DunedinPoAm to quantify biological aging. Age differences in DunedinPoAm
parallel population demographic patterns of mortality risk. In the Understanding Society sample,
older adults had faster DunedinPoAm as compared to younger ones. In the NAS sample, partici-
pants’ DunedinPoAm values increased as they aged. These observations are consistent with the
well-documented acceleration of mortality risk with advancing chronological age (Robine, 2011).
However, it sets DunedinPoAm apart from other indices of biological aging, which are not known to
register this acceleration (Finch and Crimmins, 2016; Li et al., 2020). DunedinPoAm may therefore
provide a novel tool for testing how the rate of aging changes across the life course and whether, as
demographic data documenting so-called ‘mortality plateaus’ suggest, processes of aging slow
down at the oldest chronological ages (Barbi et al., 2018).
DunedinPoAm is related to but distinct from alternative approaches to quantification of biological
aging. DunedinPoAm was moderately correlated with aging rates measured by the epigenetic clocks
proposed by Hannum et al. (2013); Levine et al. (2018) as well as KDM Biological Age derived
from clinical biomarker data (Klemera and Doubal, 2006; Levine, 2013), and with self-rated health.
Consistent with findings for the measured Pace of Aging (Belsky et al., 2018b), DunedinPoAm was
only weakly correlated with the multi-tissue clock proposed by Horvath. DunedinPoAm was more
strongly correlated with a clinical-biomarker measure of biological age, with self-rated health, with
functional test-performance and decline, and with morbidity and mortality as compared to the epi-
genetic clocks.
Third, DunedinPoAm is already variable by young adulthood and is accelerated in young people
at risk for eventual shortened healthspan. E-Risk young adults who grew up in socioeconomically dis-
advantaged families or who were exposed to victimization early in life already showed accelerated
DunedinPoAm by age 18, consistent with epidemiological observations of shorter healthy lifespan
for individuals with these exposures (Adler and Rehkopf, 2008; Danese and McEwen, 2012). We
previously found that Dunedin Study members with histories of early-life adversity showed acceler-
ated Pace of Aging in their 30 s (Belsky et al., 2017). DunedinPoAm analysis of the E-Risk cohort
suggests effects may be already manifest at least a decade earlier. DunedinPoAm may therefore
provide a useful index that can be applied to evaluate prevention programs to buffer at-risk youth
against health damaging effects of challenging circumstances.
Fourth, DunedinPoAm analysis of the CALERIE trial provided proof-of-concept for using Dunedin-
PoAm to quantify biological aging in geroprotector intervention studies. DunedinPoAm measures
the rate of aging over the recent past. Control-arm participants’ baseline DunedinPoAm correlated
positively with their clinical-biomarker pace of aging over the two years of the trial, consistent with
the hypothesis that their rate of aging was not altered. In contrast, there was no relationship
between DunedinPoAm and clinical-biomarker pace of aging for caloric-restriction-arm participants,
consistent with the hypothesis that caloric restriction altered participants’ rate of aging. Ultimately,
data on DunedinPoAm for all CALERIE participants (and participants in other geroprotector trails) at
trial baseline and follow-up will be needed to establish utility of DunedinPoAm as a surrogate end-
point. In the mean-time, these data establish potential to use DunedinPoAm as a pre-treatment
covariate in geroprotector trials to boost statistical power (Kahan et al., 2014) or to screen partici-
pants for enrollment, for example to identify those who are aging more rapidly and may therefore
show larger effects of treatment.
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We acknowledge limitations. Foremost, DunedinPoAm is a first step toward a single-assay cross-
sectional measurement of Pace of Aging. The relatively modest size of the Dunedin cohort and the
lack of other cohorts that have the requisite three or more waves of repeated biomarkers to measure
the Pace of Aging limited sample size for our machine-learning analysis to develop methylation algo-
rithms. As Pace of Aging is measured in additional cohorts, more refined analysis to develop Dune-
dinPoAm-type algorithms will become possible. A related issue is scaling of DunedinPoAm. The
original Pace of Aging measure from which DunedinPoAm was developed is denominated in ‘years’
of physiological decline occurring per 12 months of calendar time. Units of DunedinPoAm can, in
principle, be interpreted in the same way. But replication in additional cohorts is needed. In addi-
tion, our work thus far has not addressed population diversity in biological aging. The Dunedin
cohort in which DunedinPoAm was developed and the Understanding Society, NAS, and E-Risk
cohorts and CALERIE trial sample in which it was tested were mostly of white European descent. Fol-
low-up of DunedinPoAm in more diverse samples is needed to establish cross-population validity.
Finally, because methylation data are not yet available from CALERIE follow-up assessments, we
could not test if intervention modified DunedinPoAm at outcome. Ultimately, to establish Dunedin-
PoAm as a surrogate endpoint for healthspan, it will be necessary to establish not only robust associ-
ation with healthy lifespan phenotypes and modifiability by intervention, but also the extent to which
changes in DunedinPoAm induced by intervention correspond to changes in healthy-lifespan pheno-
types (Prentice, 1989).
Within the bounds of these limitations, our analysis establishes proof-of-concept for Dunedin-
PoAm as a single-time-point measure that quantifies Pace of Aging from a blood test. It can be
implemented in Illumina 450 k and EPIC array data, making it immediately available for testing in a
wide range of existing datasets as a complement to existing methylation measures of aging. Criti-
cally, DunedinPoAm offers a unique measurement for intervention trials and natural experiment
studies investigating how the rate of aging may be changed by behavioral or drug therapy, or by
environmental modification. DunedinPoAm may be especially valuable to studies that collect data
outside of clinical settings and lack blood chemistry, hematology, and other data needed to measure
aging-related changes to physiology.
Materials and methods
Data sources
Data were used from five studies: the Dunedin Study, the Understanding Society Study, the Norma-
tive Aging Study (NAS), the Environmental Risk (E-Risk) Longitudinal Twin Study, and the CALERIE
Trial. The five datasets and measures analyzed within each of them are described below.
The Dunedin Study is a longitudinal investigation of health and behavior in a complete birth
cohort. Study members (N = 1,037; 91% of eligible births; 52% male) were all individuals born
between April 1972 and March 1973 in Dunedin, New Zealand (NZ), who were eligible based on res-
idence in the province and who participated in the first assessment at age 3. The cohort represents
the full range of socioeconomic status on NZ’s South Island and matches the NZ National Health
and Nutrition Survey on key health indicators (e.g., BMI, smoking, GP visits) (Poulton et al., 2015).
The cohort is primarily white (93%) (Poulton et al., 2015). Assessments were carried out at birth and
ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, 38 and, most recently, 45 years, when 94% of the 997 study
members still alive took part. At each assessment, each study member is brought to the research
unit for a full day of interviews and examinations. Study data may be accessed through agreement
with the Study investigators (https://moffittcaspi.trinity.duke.edu/research-topics/dunedin). Dunedin
Study measures of physical and cognitive functioning and subjective signs of aging are described in
detail in Supplementary file 1H.
Understanding Society is an ongoing panel study of the United Kingdom population (https://
www.understandingsociety.ac.uk/). During 2010–12, participants were invited to take part in a
nurse’s exam involving a blood draw. Of the roughly 20,000 participants who provided clinical data
in this exam, methylation data have been generated for just under 1200. We analyzed data from
1175 participants with available methylation and blood chemistry data. Documentation of the meth-
ylation (University of Essex, 2012) and blood chemistry (University of Essex, 2017) data resource
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is available online (https://www.understandingsociety.ac.uk/sites/default/files/downloads/documen-
tation/health/user-guides/7251-UnderstandingSociety-Biomarker-UserGuide-2014.pdf).
Klemera-Doubal method (KDM) Biological Age. We measured KDM Biological age from blood
chemistry, systolic blood pressure, and lung-function data using the algorithm proposed by
Klemera and Doubal (2006) trained in data from the NHANES following the method originally
described by Levine (2013) and using the dataset compiled by Hastings (Hastings et al., 2019). We
included 8 of Levine’s original 10 biomarkers in the algorithm: albumin, alkaline phosphatase (log),
blood urea nitrogen, creatinine (log), C-reactive protein (log), HbA1C, systolic blood pressure, and
forced expiratory volume in 1 s (FEV1). We omitted total cholesterol because of evidence this bio-
marker shows different directions of association with aging in younger and older adults
(Arbeev et al., 2016). Cytomegalovirus optical density was not available in the Understanding Soci-
ety database.
Self Rated Health. Understanding Society participants rated their health as excellent, very-good,
good, fair, or poor. We standardized this measure to have Mean = 0, Standard Deviation = 1 for
analysis.
The Normative Aging Study (NAS) is an ongoing longitudinal study on aging established by the
US Department of Veterans Affairs in 1963. Details of the study have been published previously
(Bell et al., 1972). Briefly, the NAS is a closed cohort of 2280 male veterans from the Greater Boston
area enrolled after an initial health screening to determine that they were free of known chronic
medical conditions. Participants have been re-evaluated every 3–5 years on a continuous rolling basis
using detailed on-site physical examinations and questionnaires. DNA from blood samples was col-
lected from 771 participants beginning in 1999. We analyzed blood DNA methylation data from up
to four repeated assessments conducted through 2013 (Gao et al., 2019b; Panni et al., 2016). Of
the 771 participants with DNA methylation data, n = 536 (46%) had data from two repeated assess-
ments and n = 178 (23%) had data from three or four repeated assessments. We restricted the cur-
rent analysis to participants with at least one DNA methylation data point. The NAS was approved
by the Department of Veterans Affairs Boston Healthcare System and written informed consent was
obtained from each subject before participation.
Mortality. Regular mailings to study participants have been used to acquire vital-status information
and official death certificates were obtained from the appropriate state health department to be
reviewed by a physician. Participant deaths are routinely updated by the research team and the last
available update was on 31 December 2013. During follow-up, n = 355 (46%) of the 771 NAS partici-
pants died.
Chronic Disease Morbidity. We measured chronic disease morbidity from participants medical his-
tories and prior diagnoses (Gao et al., 2019a; Gao et al., 2019c; Lepeule et al., 2018;
Nyhan et al., 2018). We counted the number of chronic diseases to compose an ordinal index with
categories of 0, 1, 2, 3, or 4+ of the following comorbidities: hypertension, type-2 diabetes, cardio-
vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, and cancer.
The Environmental Risk (E-Risk) Longitudinal Twin Study tracks the development of a birth cohort
of 2,232 British participants. The sample was drawn from a larger birth register of twins born in Eng-
land and Wales in 1994–1995. Full details about the sample are reported elsewhere (Moffitt and
E-Risk Study Team, 2002). Briefly, the E-Risk sample was constructed in 1999–2000, when 1116 fami-
lies (93% of those eligible) with same-sex 5-year-old twins participated in home-visit assessments. This
sample comprised 56% monozygotic (MZ) and 44% dizygotic (DZ) twin pairs; sex was evenly distrib-
uted within zygosity (49% male). Families were recruited to represent the UK population of families
with newborns in the 1990 s, on the basis of residential location throughout England and Wales and
mother’s age. Teenaged mothers with twins were over-selected to replace high-risk families who were
selectively lost to the register through non-response. Older mothers having twins via assisted repro-
duction were under-selected to avoid an excess of well-educated older mothers. The study sample
represents the full range of socioeconomic conditions in the UK, as reflected in the families’ distribu-
tion on a neighborhood-level socioeconomic index (ACORN [A Classification of Residential Neighbor-
hoods], developed by CACI Inc for commercial use): 25.6% of E-Risk families lived in ‘wealthy achiever’
neighborhoods compared to 25.3% nationwide; 5.3% vs. 11.6% lived in ‘urban prosperity’ neighbor-
hoods; 29.6% vs. 26.9% lived in ‘comfortably off’ neighborhoods; 13.4% vs. 13.9% lived in ‘moderate
means’ neighborhoods, and 26.1% vs. 20.7% lived in ‘hard-pressed’ neighborhoods. E-Risk underre-
presents ‘urban prosperity’ neighborhoods because such households are likely to be childless.
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Home-visits assessments took place when participants were aged 5, 7, 10, 12 and, most recently,
18 years, when 93% of the participants took part. At ages 5, 7, 10, and 12 years, assessments were
carried out with participants as well as their mothers (or primary caretakers); the home visit at age
18 included interviews only with participants. Each twin was assessed by a different interviewer.
These data are supplemented by searches of official records and by questionnaires that are mailed,
as developmentally appropriate, to teachers, and co-informants nominated by participants them-
selves. The Joint South London and Maudsley and the Institute of Psychiatry Research Ethics Com-
mittee approved each phase of the study. Parents gave informed consent and twins gave assent
between 5–12 years and then informed consent at age 18. Study data may be accessed through
agreement with the Study investigators (https://moffittcaspi.trinity.duke.edu/research-topics/erisk).
Childhood Socioeconomic Status (SES). Childhood SES was defined through a standardized com-
posite of parental income, education, and occupation (Trzesniewski et al., 2006). The three SES
indicators were highly correlated (r = 0.57–0.67) and loaded significantly onto one factor. The popu-
lation-wide distribution of the resulting factor was divided in tertiles for analyses.
Childhood Victimization. As previously described (Danese et al., 2017), we assessed exposure to
six types of childhood victimization between birth to age 12: exposure to domestic violence
between the mother and her partner, frequent bullying by peers, physical and sexual harm by an
adult, and neglect.
The CALERIE Trial is described in detail elsewhere (Ravussin et al., 2015). Briefly, N = 220 nor-
mal-weight (22.0  BMI < 28 kg/m2) participants (70% female, 77% white) aged 21–50 years at base-
line were randomized to caloric restriction or ad libitum conditions with a 2:1 ratio (n = 145 to
caloric restriction, n = 75 to ad libitum). ‘Ad libitum’ (normal) caloric intake was determined from
two consecutive 14 day assessments of total daily energy expenditure using doubly labeled water
(Redman et al., 2014). Average percent caloric restriction over six-month intervals was retrospec-
tively calculated by the intake-balance method with simultaneous measurements of total daily energy
expenditure using doubly labeled water and changes in body composition (Racette et al., 2012;
Wong et al., 2014). Over the course of the trial, participants in the caloric-restriction arm averaged
12% reduction in caloric intake (about half the prescribed reduction). Participants in the ad libitum
condition reduced caloric intake by <2% (Ravussin et al., 2015). CALERIE data are available at
https://calerie.duke.edu/samples-data-access-and-analysis.
Klemera-Doubal method (KDM) Biological Age. KDM Biological age was measured according to
the procedure described in our previous article (Belsky et al., 2018a). Briefly, we computed KDM
Biological Age from CALERIE blood chemistry and blood pressure data using the algorithm pro-
posed by Klemera and Doubal (2006) trained in data from the NHANES following the method orig-
inally described by Levine (2013) and NHANES data from years matched to the timing of the
CALERIE Trial. We included 8 of Levine’s original 10 biomarkers in the algorithm: albumin, alkaline
phosphatase (log), blood urea nitrogen, creatinine (log), C-reactive protein (log), HbA1C, systolic
blood pressure, and total cholesterol. Cytomegalovirus optical density and lung function were not
measured in CALERIE. We supplemented the algorithm with data on uric acid and white blood cell
count.
DNA methylation data
DNA methylation was measured from Illumina 450 k Arrays in the Dunedin Study, NAS, and E-Risk
Study and from Illumina EPIC 850 k Arrays in the Understanding Society study and the CALERIE
Trial. DNA was derived from whole blood samples in all studies. Dunedin Study blood draws were
conducted at the cohort’s age-38 assessment during 2010–12. Understanding Society blood draws
were conducted in 2012. NAS blood draws were conducted during 1999–2013. E-Risk blood draws
were conducted at the cohort’s age-18 assessment during 2012–13. CALERIE blood draws were con-
ducted at the trial baseline assessment in 2007. Dunedin and CALERIE methylation assays were run
by the Molecular Genomics Shared Resource at Duke Molecular Physiology Institute, Duke University
(USA). Understanding Society and E-Risk assays were run by the Complex Disease Epigenetics
Group at the University of Exeter Medical School (UK) (www.epigenomicslab.com). NAS methylation
assays were run by the Genome Research Core of the University of Illinois at Chicago. Processing
protocols for the methylation data from all studies have been described previously (Dai et al., 2017;
Hannon et al., 2018; Marzi et al., 2018; Panni et al., 2016). (CALERIE data were processed accord-
ing to the same protocols used for the Dunedin Study.)
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Methylation clocks
We computed the methylation clocks proposed by Horvath, Hannum, and Levine using the methyla-
tion data provided by the individual studies and published algorithms (Hannum et al., 2013; Hor-
vath, 2013; Levine et al., 2018).
DunedinPoAm
The Dunedin Pace of Aging methylation algorithm (DunedinPoAm) was developed using elastic-net
regression analysis carried out in the Dunedin Study, as described in detail in the Results. The crite-
rion variable was Pace of Aging. Development of the Pace of Aging is described in detail elsewhere
(Belsky et al., 2015). Briefly, we conducted mixed-effects growth modeling of longitudinal change
in 18 biomarkers measuring integrity of the cardiovascular, metabolic, renal, hepatic, pulmonary,
periodontal, and immune systems. Biomarkers were measured at the age 26, 32, and 38 assess-
ments: in order of listing in Figure 3 of Belsky et al. (2015) glycated hemoglobin, cardiorespiratory
fitness, waist-hip ratio, FEV1/FVC ratio, FEV1, mean arterial pressure, body mass index, leukocyte
telomere length, creatinine clearance, blood urea nitrogen, lipoprotein (a), triglycerides, gum health,
total cholesterol, white blood cell count, high-sensitivity C-reactive protein, HDL cholesterol,
ApoB100/ApoA1 ratio. For each biomarker, we estimated random slopes quantifying each partici-
pant’s own rate of change in that biomarker. We then composited slopes across the 18 biomarkers
to calculate a participant’s Pace of Aging. Pace of Aging was scaled in units representing the mean
trend in the cohort, that is the average physiological change occurring during one calendar year
(N = 954, M = 1, SD = 0.38). Of the N = 819 Dunedin Study members with methylation data at age
38, N = 810 had measured Pace of Aging (M = 0.98, SD = 0.09). This group formed the analysis sam-
ple to develop DunedinPoAm.
To compute DunedinPoAm in the Understanding Society, NAS, E-Risk, and CALERIE Trial datasets,
we applied the scoring algorithm estimated from elastic net regression in the Dunedin Study. CpG
weights for the scoring algorithm are provided in Supplementary file 1A. R code to implement the
scoring algorithm in data from Illumina 450 k and EPIC arrays is provided at https://github.com/dan-
belsky/DunedinPoAm38 .
Bootstrap repetition analysis to estimate out-of-sample correlation between
methylation Pace of Aging (mPoA) measures and longitudinal Pace of
Aging
The Dunedin Study is the only dataset to include measured 12 year longitudinal Pace of Aging. To
estimate the out-of-sample correlation between mPoA and the original Pace of Aging measure, we
conducted 90/10 crossfold validation analysis. We randomly selected 90% of the cohort to serve as
the ‘training’ sample in which the mPoA algorithm was developed. We used the remaining 10% to
form a ‘test’ sample to estimate the correlation between mPoA and Pace of Aging. We repeated
this analysis across 100 bootstrap repetitions. In each repetition, we randomly sampled 90% of the
cohort to use in the training analysis and reserved the remaining 10% for testing.
The mPoA algorithms developed across the 100 bootstrap repetitions included different sets of
CpGs (range of 21–209 CpGs selected, M = 54, SD = 27 CpGs). However, the resulting algorithms
were highly correlated (mean pairwise r = 0.90, SD = 0.14). The average correlation between the
90%-trained mPoA and longitudinal Pace of Aging in the 10% test samples was (r = 0.33,
SD = 0.10). Details are reported in Figure 1—figure supplement 2.
Statistical analysis
We conducted analysis of Dunedin, Understanding Society, NAS, E-Risk, and CALERIE data using
regression models. We analyzed continuous outcome data using linear regression. We analyzed
count outcome data using Poisson regression. We analyzed time-to-event outcome data using Cox
proportional hazard regression. For analysis of repeated-measures longitudinal DNA methylation
data in the NAS, we used generalized estimating equations to account for non-independence of
repeated observations of individuals (Ballinger, 2004), following the method in previous analysis of
those data (Gao et al., 2018), and econometric fixed-effects regression (Wooldridge, 2012) to test
within-person change over time. For analysis in E-Risk, which include data on twin siblings, we clus-
tered standard errors at the family level to account for non-independence of data. For analysis of
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longitudinal change in clinical-biomarker biological age in CALERIE, we used mixed-effects growth
models (Singer and Willett, 2003) following the method in our original analysis of those data
(Belsky et al., 2018a). For regression analysis, methylation measures were adjusted for batch effects
by regressing the measure on batch controls and predicting residual values. Dunedin Study, Under-
standing Society, E-Risk, and CALERIE analyses included covariate adjustment for sex (the NAS
included only men). Understanding Society, NAS, and CALERIE analyses included covariate adjust-
ment for chronological age. (Dunedin and E-Risk are birth-cohort studies and participants are all the
same chronological age.) Sensitivity analyses testing covariate adjustment for estimated leukocyte
distributions and smoking are reported in Supplementary file 1C-G.
Sensitivity analyses
We tested sensitivity of methylation Pace of Aging (mPoA) measures to alternative methods of normal-
izing DNAmethylation data. We normalized data using the ‘methylumi’ and ‘minfi’ packages and com-
puted correlations between mPoA measures derived from these two datasets. The correlation was
r = 0.94.
The elastic net model selected 46 CpGs to compose the mPoA. One of these CpGs, cg11897887,
has been identified as an mQTL (Volkov et al., 2016). To evaluate sensitivity of results to the exclu-
sion of this CpGs, we computed a version of the mPoA excluding this CpG and repeated analysis.
This version of the score was correlated with the full mPoA at r = 1. Results were the same in analy-
ses with both versions (available from the authors upon request).
Another CpG selected in the elastic net, cg05575921, is located within the gene AHRR, previously
identified as a methylation site modified by tobacco exposure and associated with lung cancer and
other chronic disease, for example (Fasanelli et al., 2015; Reynolds et al., 2015). We tested sensi-
tivity of results to the exclusion of this probe using the method described above. This version of the
score was correlated with the full mPoA at r = 0.94. Again, results were the same in analyses with
both versions (available from the authors upon request).
Code for analysis
Code used for analysis and to prepare figures is accessible via https://github.com/danbelsky/Dune-
dinPoAm_eLife2020.git (Belsky, 2020; copy archived at https://github.com/elifesciences-publica-
tions/DunedinPoAm_eLife2020).
Code to calculate DunedinPoAm from Illumina 450 k or Epic Array Data. R code is
available at https://github.com/danbelsky/DunedinPoAm38.git.
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